Department of Endocrinology, Metabolism and Diabetes Mellitus, Sismanogleio-Amalia Fleming General Hospital, 25th Martiou Str. 14, Melissia 15127, Athens, Greece.
Second Department of Dermatology and Venereology, National and Kapodistrian University of Athens, "Atticon" University General Hospital, Athens, Greece.
Hormones (Athens). 2024 Mar;23(1):89-95. doi: 10.1007/s42000-023-00470-6. Epub 2023 Jul 29.
To evaluate the response (titers of anti-COVID-19 antibodies) to COVID-19 mRNA vaccine of patients with Hashimoto's thyroiditis and normal individuals.
Twenty-four patients with Hashimoto's thyroiditis and 51 normal individuals were studied after the third dose of the vaccine.
Patients with Hashimoto's thyroiditis showed significantly higher immune response after the third dose of the COVID-19 mRNA vaccine compared with normal individuals (p = 0.020). After elimination of the four smokers with Hashimoto's thyroiditis, the immune response between the remaining 20 non-smoking patients compared with the response of the 23 non-smoking normal individuals was not different (p = 0.564). There was a significant positive correlation of the anti-COVID-19 antibodies with BMI (p = 0.029) but not with waist circumference in the patients with Hashimoto's thyroiditis (p = 0.054). Similar correlations were not found in normal individuals. Waist circumference could be considered as representative of visceral adipose tissue. In obese normal individuals (BMI ≥ 30), anti-COVID-19 antibodies were not different from those in lean normal individuals (BMI < 25). In obese patients with Hashimoto's thyroiditis, anti-COVID-19 antibodies were significantly higher compared to those in lean patients (p = 0.013). Median anti-COVID-19 antibody titer in obese patients with Hashimoto's thyroiditis was also significantly higher compared to that in obese normal individuals (p = 0.009).
Patients with Hashimoto's thyroiditis show significantly higher immune response after the third dose of the COVID-19 mRNA vaccine compared with normal individuals. Obese patients with Hashimoto's thyroiditis show additionally a significantly higher immune response compared with lean patients.
评估桥本甲状腺炎患者和正常个体对 COVID-19 mRNA 疫苗的反应（抗 COVID-19 抗体滴度）。
在接种第三剂疫苗后，研究了 24 名桥本甲状腺炎患者和 51 名正常个体。
与正常个体相比，桥本甲状腺炎患者在接种第三剂 COVID-19 mRNA 疫苗后表现出明显更高的免疫反应（p=0.020）。排除了 4 名桥本甲状腺炎吸烟者后，与 23 名非吸烟正常个体的反应相比，其余 20 名非吸烟患者之间的免疫反应没有差异（p=0.564）。桥本甲状腺炎患者的抗 COVID-19 抗体与 BMI 呈显著正相关（p=0.029），但与腰围无关（p=0.054）。在正常个体中未发现类似的相关性。腰围可以被认为是内脏脂肪组织的代表。在肥胖的正常个体（BMI≥30）中，抗 COVID-19 抗体与瘦的正常个体没有差异（BMI<25）。在肥胖的桥本甲状腺炎患者中，抗 COVID-19 抗体明显高于瘦患者（p=0.013）。肥胖的桥本甲状腺炎患者的抗 COVID-19 抗体中位数也明显高于肥胖的正常个体（p=0.009）。
与正常个体相比，桥本甲状腺炎患者在接种第三剂 COVID-19 mRNA 疫苗后表现出明显更高的免疫反应。肥胖的桥本甲状腺炎患者与瘦患者相比，免疫反应明显更高。
